Sunday, November 29, 2015

What Comes Down Must Go Up?

Readers may recall the September Daraprim kerfluffle, regarding the preferred treatment of the potentially deadly (but rare) "parasitic infection called toxoplasmosis." Briefly, Turing had purchased the rights to the medication used to fight the infection, and then boosted its price from about $13 to $750. The company eventually promised to back off the spike.

But that was then (two months ago) and this is now:

"Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.Instead, the small biotech company is reducing what it charges hospitals, by up to 50 percent, for its parasitic infection treatment"

Which is great news (well, for certain values of "great:" after all, it does represent a pretty hefty increase over its pre-Turing cost) for hospitalized patients, but what about those playing along at home?

The bad news is that the $750-a-copy price will apparently stand.

The good news is that Imprimis Pharmaceuticals, a competitor, is making available a low-cost alternative.

How low-cost?

This low-cost:


The only real challenge right now is getting insurers to cover it. My take is that, at $1 a pop, that really shouldn't be a major issue.
blog comments powered by Disqus